Literature DB >> 14647305

Systemic tumor targeting and killing by Sindbis viral vectors.

Jen-Chieh Tseng1, Brandi Levin, Alicia Hurtado, Herman Yee, Ignacio Perez de Castro, Maria Jimenez, Peter Shamamian, Ruzhong Jin, Richard P Novick, Angel Pellicer, Daniel Meruelo.   

Abstract

Successful cancer gene therapy requires a vector that systemically and specifically targets tumor cells throughout the body. Although several vectors have been developed to express cytotoxic genes via tumor-specific promoters or to selectively replicate in tumor cells, most are taken up and expressed by just a few targeted tumor cells. By contrast, we show here that blood-borne Sindbis viral vectors systemically and specifically infect tumor cells. A single intraperitoneal treatment allows the vectors to target most tumor cells, as demonstrated by immunohistochemistry, without infecting normal cells. Further, Sindbis infection is sufficient to induce complete tumor regression. We demonstrate systemic vector targeting of tumors growing subcutaneously, intrapancreatically, intraperitoneally and in the lungs. The vectors can also target syngeneic and spontaneous tumors in immune-competent mice. We document the anti-tumor specificity of a vector that systemically targets and eradicates tumor cells throughout the body without adverse effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14647305     DOI: 10.1038/nbt917

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  48 in total

Review 1.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Vesicular stomatitis virus modified with single chain IL-23 exhibits oncolytic activity against tumor cells in vitro and in vivo.

Authors:  James M Miller; Sarah McNulty Bidula; Troels Mygind Jensen; Carol Shoshkes Reiss
Journal:  Int J Interferon Cytokine Mediat Res       Date:  2010-05-01

Review 3.  Noninvasive biophotonic imaging for studies of infectious disease.

Authors:  Nuria Andreu; Andrea Zelmer; Siouxsie Wiles
Journal:  FEMS Microbiol Rev       Date:  2010-10-19       Impact factor: 16.408

4.  Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.

Authors:  Tomer Granot; Yoshihide Yamanashi; Daniel Meruelo
Journal:  Mol Ther       Date:  2013-09-12       Impact factor: 11.454

5.  The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9.

Authors:  Bassel Akache; Dirk Grimm; Kusum Pandey; Stephen R Yant; Hui Xu; Mark A Kay
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

6.  Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo.

Authors:  Pong-Yu Huang; Jih-Huong Guo; Lih-Hwa Hwang
Journal:  Mol Ther       Date:  2011-11-08       Impact factor: 11.454

Review 7.  RNA interference: ready to silence cancer?

Authors:  Simone Mocellin; Rodolfo Costa; Donato Nitti
Journal:  J Mol Med (Berl)       Date:  2005-11-09       Impact factor: 4.599

Review 8.  Structure-guided identification of a laminin binding site on the laminin receptor precursor.

Authors:  Kelly V Jamieson; Stevan R Hubbard; Daniel Meruelo
Journal:  J Mol Biol       Date:  2010-10-30       Impact factor: 5.469

9.  Sindbis virus replication, is insensitive to rapamycin and torin1, and suppresses Akt/mTOR pathway late during infection in HEK cells.

Authors:  Vidyarani Mohankumar; Nisha R Dhanushkodi; Ramaswamy Raju
Journal:  Biochem Biophys Res Commun       Date:  2011-02-18       Impact factor: 3.575

10.  Oncolytic activity of Sindbis virus in human oral squamous carcinoma cells.

Authors:  K Saito; K Uzawa; A Kasamatsu; K Shinozuka; K Sakuma; M Yamatoji; M Shiiba; Y Shino; H Shirasawa; H Tanzawa
Journal:  Br J Cancer       Date:  2009-07-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.